Coherus BioSciences Inc (NAS:CHRS)
$ 1.77 0.01 (0.57%) Market Cap: 203.06 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc To discuss FDA Approval of LOQTORZI Transcript

Oct 27, 2023 / 08:30PM GMT
Release Date Price: $2.64 (-3.65%)
McDavid Stilwell
Coherus BioSciences, Inc. - CFO

This is McDavid Stilwell, Chief Financial Officer of Coherus BioSciences. We issued a press release earlier announcing the U.S. FDA approval of LOQTORZI for the treatment of nasopharyngeal carcinoma. This release can be found on the Coherus Biosciences' website.

Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include, but are not limited to, our ability to enter into future partnerships and approval for new products and to launch our products in a timely manner, projections of future financial performance, including expenses and revenue, projections of future market share for any product and our expectations for market opportunity for any indication.

All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievements to differ from those implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot